ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS ATHE 深 沪
等待开盘 12-20 09:30:00 美东时间
3.1002
+0.070
+2.32%
华盛通- 最 高3.12
- 今 开3.04
- 成交量 4067股
- 最 低 3.04
- 昨 收 3.03
- 总市值 5619.33万
- 52周最高 7.00
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 2.5209
- 委 比 99.48%
- 总股本 1812.57万
- 历史最高 51.50
- 量 比 0.58
- 振 幅 2.64%
- 历史最低 1.001
- 每 手 1
- 风险率 0.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alterity Therapeutics Announces Director Departure
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
11-24 11:28
Alterity Therapeutics CEO Outlines Strategic Vision
Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeut...
11-21 09:07
Alterity Therapeutics Advances in Neurodegenerative Disease Treatment
Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics...
11-21 08:57
Alterity Therapeutics Announces Board Restructuring for Growth
An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alte...
11-21 07:28
Alterity Therapeutics Discloses Equity Derivative Positions
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
11-13 12:48
Alterity Therapeutics Presents Data On Orthostatic Hypotension From Its ATH434-201 Phase 2 Clinical Study In Multiple System Atrophy
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that analyses on
11-10 20:27
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
Double-blind trial data shows increased efficacy of ATH434 at high doses, while open-label trial results confirm similar benefits in advanced MSA. ATH434 has a potential peak sales opportunity of $2.4 billion globally. Alterity's cash balance as of September 2025 is A$54.56M. The company is engaging with the FDA to advance ATH434 toward Phase 3 trials, with an End-of-Phase 2 meeting expected in mid-2026. Positive clinical outcomes and regulatory ...
10-31 11:25
OceanPal Closes $120M PIPE To Launch SovereignAI, Positioning As Public Investment Vehicle To NEAR Protocol And AI-Driven Blockchain Infrastructure
OceanPal launches SovereignAI focused on commercializing the NEAR Protocol Deep alignment on a shared vision for universal AI sovereignty with the NEAR Foundation will facilitate the implementation of a NEAR
10-28 21:14
Hasbro Q3 Boosted By Wizards Growth, Outlook Raised
Hasbro reports Q3 beats with 8% sales growth, Wizards-driven gains, higher profits, and raised full-year revenue and EBITDA guidance outlook.
10-23 21:53
Garmin teams up with Truemed to unlock HSA/FSA funds for fitness products
Reimbursement program allows qualified U.S. customers to use pre-tax dollars on smartwatches and cycling products OLATHE, Kan., Oct. 23, 2025 /PRNewswire/ -- Garmin (NYSE: GRMN) is teaming ...
10-23 19:00
